| Source DB | nl |
|---|
| Institution | KU Leuven |
|---|
| Code | e3957b8d-67ce-4832-8be7-f9a9ccdd21d1 |
|---|
| Unit | 61a9f0d7-1f47-46b1-9a91-25973d85f88e
|
|---|
| Begin | 12/1/2019 |
|---|
| End | 11/30/2020 |
|---|
| title fr |
|
|---|
| title nl | Anti-MDA5 auto-antilichamen in de pathogenese van myositis.
|
|---|
| title en | Anti-MDA5 autoantibodies in the pathogenesis of myositis.
|
|---|
| Description fr |
|
|---|
| Description nl | Interstitiële longziekte in de context van anti-MDA5-antilichamen is een levensbedreigende aandoening. De hypothese van dit project, een samenwerking tussen de KU Leuven en het Karolinska Instituut, stelt dat anti-MDA auto-antilichamen rechtstreeks bijdragen aan de pathogene mechanismen. We zullen anti-MDA5-antilichamen zuiveren en de pathogeniteit in vitro beoordelen op spiercellen en longfibroblasten. Dit zal de basis vormen voor verder onderzoek naar de impact van anti-MDA5-antilichamen in vivo.
|
|---|
| Description en | Interstitial lung disease in the context of anti-MDA5 antibodies is a life-threatening condition. The hypothesis of this project, a collaboration between KU Leuven and Karolinska Institute states that anti-MDA autoantibodies directly contribute to the pathogenic mechanisms. We will purify anti-MDA5 antibodies and assess pathogenicity in vitro, on muscle cells and lung fibroblasts. This will set the stage to further study the impact of anti-MDA5 antibodies in vivo.
|
|---|
| Qualifiers | - Interstitial lung disease - Interstitiële longziekte - anti-MDA5 antibodies - myositis - |
|---|
| Personal | De Langhe Ellen |
|---|
| Collaborations | |
|---|
